Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genetics of QT Response to Moxifloxacin
NCT01936480Phase 4Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- Oct 2013
- Primary completion
- Jun 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of moxifloxacin in cardiac arrhythmia, sponsored by Massachusetts General Hospital. Primary endpoint: QT interval duration at 6 hours. Started Oct 2013; status: terminated.
02
Drugs
moxifloxacin
03
Conditions
cardiac arrhythmia
Beyond the preview
Go deeper on NCT01936480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01936480.